Examining the Role of Docetaxel with Radiation Therapy and ADT in Non-Metastatic Prostate Cancer – Anthony D’Amico & Philip Kantoff

Following androgen deprivation therapy (ADT) which was introduced decades prior, the TAX-327 trial of docetaxel for patients with metastatic castration-resistant prostate cancer was the first to demonstrate a survival advantage for systemic treatment in prostate cancer. Since then, docetaxel has proven survival benefit for men with metastatic castration-sensitive disease. However, the benefit…

Read the full article here

Related Articles